Kyverna Therapeutics, Inc. KYTX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s additional paid-in capital?
- Kyverna Therapeutics, Inc. (KYTX) reported additional paid-in capital of $660.23M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Kyverna Therapeutics, Inc.'s additional paid-in capital increased by 24.1% year-over-year, from $532.17M to $660.23M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s additional paid-in capital has grown at a 1089.7% compound annual growth rate (CAGR), from $4.64M to $657.01M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.